Your session is about to expire
← Back to Search
MetAP2 Inhibition for Aging (BIO-AGE Trial)
N/A
Waitlist Available
Led By Lauren Sparks, PhD
Research Sponsored by AdventHealth Translational Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
BIO-AGE Trial Summary
This trial studies how a protein affects fat tissue in young & old people, in the lab.
Who is the study for?
This trial is for healthy young adults aged 18-30 and seniors 65 or older with a BMI ≤ 40 kg/m2, who are sedentary, weight stable, and can understand English. They must be willing to follow the study plan. People with drug/alcohol abuse history, unstable medical conditions, recent tobacco use, certain allergies or infections like HIV/Hepatitis B/C, diabetes, untreated hypertension or those on specific medications cannot join.Check my eligibility
What is being tested?
The study aims to collect fat tissue from participants to examine how blocking a protein called MetAP2 affects it in the lab. This could help understand aging-related changes in body fat.See study design
What are the potential side effects?
Since this trial involves collecting adipose tissue through biopsy there may be local pain, bruising or infection at the site of tissue removal. There's also a small risk of bleeding or an allergic reaction to local anesthesia used during the procedure.
BIO-AGE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The effect of MetAP2 inhibition on adipose tissue quality in adipose tissue explants
The effect of MetAP2 inhibition on senescence markers in adipose tissue explants
BIO-AGE Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Younger with MetAP2 inhibitionExperimental Treatment1 Intervention
Participants between 18 and 30 years old with MetAP2 inhibition in conditioned media
Group II: Older with MetAP2 inhibitionExperimental Treatment1 Intervention
Participants 65 years old with MetAP2 inhibition in conditioned media
Group III: Younger without MetAP2 inhibitionActive Control1 Intervention
Participants between 18 and 30 years old without MetAP2 inhibition in conditioned media
Group IV: Older without MetAP2 inhibitionActive Control1 Intervention
Participants 65 years old and without MetAP2 inhibition in conditioned media
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abdominal subcutaneous adipose tissue biopsy
2015
N/A
~20
Find a Location
Who is running the clinical trial?
AdventHealth Translational Research InstituteLead Sponsor
48 Previous Clinical Trials
20,150 Total Patients Enrolled
2 Trials studying Aging
74 Patients Enrolled for Aging
Lauren Sparks, PhDPrincipal InvestigatorStudy Principal Investigator
2 Previous Clinical Trials
434 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have type 2 diabetes with an HbA1C level of 6.5 or higher.I've taken anti-inflammatory or antiplatelet meds within the week and can't stop for a biopsy.I have been diagnosed with type 1 diabetes.I am taking metformin for polycystic ovarian syndrome.I have no cancer recurrence in the last 5 years, except for skin cancer.My hemoglobin level is below normal for my gender.My blood pressure is not higher than 160/100.I do not have any severe or unstable health conditions.I exercise less than 20 minutes, three times a week.I have not had major surgery in the last 4 weeks.I use insulin and other medications for my diabetes.I am 65 years old or older.I have signed all required consent and privacy forms for the study.I am between 18 and 30 years old.I have a history of HIV or active contagious diseases like tuberculosis or hepatitis.I can speak and understand English.My weight has been stable, within about 11 pounds, for the last 3 months.I am a woman who has not started new oral contraceptives in the last 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: Younger without MetAP2 inhibition
- Group 2: Younger with MetAP2 inhibition
- Group 3: Older without MetAP2 inhibition
- Group 4: Older with MetAP2 inhibition
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Aging Patient Testimony for trial: Trial Name: NCT05989035 — N/A
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any open enrollment opportunities for this trial presently?
"Data hosted on clinicaltrials.gov reveals that this experiment is not presently recruiting patients, the first posting of which was made on August 31st 2020 and last updated 8/10/2023. Alas, 246 other research projects are actively seeking subjects at this time."
Answered by AI
Who else is applying?
What state do they live in?
Florida
What site did they apply to?
AdventHealth Translational Research Institute
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
Why did patients apply to this trial?
I am always looking for ways to age better and stay healthy.
PatientReceived 1 prior treatment
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger